177 related articles for article (PubMed ID: 15277255)
1. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
Fleming GF; Filiaci VL; Bentley RC; Herzog T; Sorosky J; Vaccarello L; Gallion H
Ann Oncol; 2004 Aug; 15(8):1173-8. PubMed ID: 15277255
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
Fleming GF; Brunetto VL; Cella D; Look KY; Reid GC; Munkarah AR; Kline R; Burger RA; Goodman A; Burks RT
J Clin Oncol; 2004 Jun; 22(11):2159-66. PubMed ID: 15169803
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
[TBL] [Abstract][Full Text] [Related]
5. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
Fleming GF; Fowler JM; Waggoner SE; Copeland LJ; Greer BE; Horowitz I; Sutton G; Schilder RJ; Fracasso PM; Ball HG; McGuire WP
J Clin Oncol; 2001 Feb; 19(4):1021-9. PubMed ID: 11181665
[TBL] [Abstract][Full Text] [Related]
7. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.
Homesley HD; Filiaci V; Gibbons SK; Long HJ; Cella D; Spirtos NM; Morris RT; DeGeest K; Lee R; Montag A
Gynecol Oncol; 2009 Mar; 112(3):543-52. PubMed ID: 19108877
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
Miller DS; Filiaci VL; Mannel RS; Cohn DE; Matsumoto T; Tewari KS; DiSilvestro P; Pearl ML; Argenta PA; Powell MA; Zweizig SL; Warshal DP; Hanjani P; Carney ME; Huang H; Cella D; Zaino R; Fleming GF
J Clin Oncol; 2020 Nov; 38(33):3841-3850. PubMed ID: 33078978
[TBL] [Abstract][Full Text] [Related]
10. Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: a clinical study and literature review.
Hall DJ; Martin DA; Kincaid K
Eur J Gynaecol Oncol; 2003; 24(6):481-9. PubMed ID: 14658586
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.
Armstrong DK; Bookman MA; McGuire W; Bristow RE; Schilder JM;
Gynecol Oncol; 2007 Jun; 105(3):667-71. PubMed ID: 17368526
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel (Taxol) plus doxorubicin plus filgrastim in advanced sarcoma: a phase II study.
Sandler A; Fox S; Meyers T; Rougraff B
Am J Clin Oncol; 1998 Jun; 21(3):241-5. PubMed ID: 9626789
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
Sternberg CN; de Mulder PH; Schornagel JH; Théodore C; Fossa SD; van Oosterom AT; Witjes F; Spina M; van Groeningen CJ; de Balincourt C; Collette L;
J Clin Oncol; 2001 May; 19(10):2638-46. PubMed ID: 11352955
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Walker JL; Moore KN; Waggoner SE; Thaker PH; Rizack T; Hoffman JS; Fracasso PM
Gynecol Oncol; 2015 Jul; 138(1):36-40. PubMed ID: 25958319
[TBL] [Abstract][Full Text] [Related]
15. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393.
Forastiere AA; Leong T; Rowinsky E; Murphy BA; Vlock DR; DeConti RC; Adams GL
J Clin Oncol; 2001 Feb; 19(4):1088-95. PubMed ID: 11181673
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296.
Wadler S; Brain C; Catalano P; Einzig AI; Cella D; Benson AB
Cancer J; 2002; 8(3):282-6. PubMed ID: 12074329
[TBL] [Abstract][Full Text] [Related]
17. [A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer].
Honma H; Sagae S; Terasawa K; Tanaka R; Chida M; Mizumoto H; Ishioka S; Saito T; Kudo R
Gan To Kagaku Ryoho; 2004 Apr; 31(4):549-53. PubMed ID: 15114698
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]